GlassScriptPhysician profile
David A Montgomery
NPI 1932462959
$8,040.48
in general payments reported to CMS, 2019-2025
51 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $1,611 · 2021: $1,470 · 2022: $909 · 2023: $801 · 2024: $539 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,441.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $651.73 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $642.81 | 2019-2025 | Jardiance |
| Abbvie INC. | $571.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $450.97 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $440.78 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $430.33 | 2019-2024 | Farxiga, Movantik |
| Amgen INC. | $339.43 | 2019-2023 | Repatha |
| Lilly USA, LLC | $253.31 | 2019-2021 | |
| Astellas Pharma US INC | $230.71 | 2019-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $181.81 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.87 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $179.08 | 2019 | |
| Merck Sharp & Dohme LLC | $159.25 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $149.84 | 2023-2025 | Rexulti |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.